Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Vergez

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|February 24, 2024
Minimal Residual Disease in Acute Myeloid Leukemia: Old and New ConceptsMathias Chea, Lucie Rigolot, Alban Canali, et al.
Cancer Immunology, Immunotherapy : CII|September 3, 2021
MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutationsThibault Comont, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
Kidney International|June 14, 2021
Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantationArnaud Del Bello, Nassim Kamar, Francois Vergez, et al.
Blood|February 24, 2026
A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemiaEkaterini Himonas, Lucie de Beauchamp, Désirée Zerbst, et al.
Haematologica|February 2, 2023
Somatic genetic alterations predict hematological progression in GATA2 deficiencyLaetitia Largeaud, Matthew Collin, Nils Monselet, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Blood|June 25, 2025
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AMLAristi Damaskou, Rachael Wilson, Malgorzata Gozdecka, et al.
Blood|June 19, 2013
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionDaniel Thomas, Jason A Powell, Francois Vergez, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|February 24, 2024
Minimal Residual Disease in Acute Myeloid Leukemia: Old and New ConceptsMathias Chea, Lucie Rigolot, Alban Canali, et al.
Cancer Immunology, Immunotherapy : CII|September 3, 2021
MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutationsThibault Comont, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
Kidney International|June 14, 2021
Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantationArnaud Del Bello, Nassim Kamar, Francois Vergez, et al.
Blood|February 24, 2026
A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemiaEkaterini Himonas, Lucie de Beauchamp, Désirée Zerbst, et al.
Haematologica|February 2, 2023
Somatic genetic alterations predict hematological progression in GATA2 deficiencyLaetitia Largeaud, Matthew Collin, Nils Monselet, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Blood|June 25, 2025
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AMLAristi Damaskou, Rachael Wilson, Malgorzata Gozdecka, et al.
Blood|June 19, 2013
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionDaniel Thomas, Jason A Powell, Francois Vergez, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
Pageof 2